PIRAMAL PHARMA
|
PIRAMAL PHARMA Last 5 Year Cashflow Statement History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|
Profit Before Tax | ₹-168 Cr | ₹441 Cr | ₹640 Cr |
Adjustment | ₹1,136 Cr | ₹787 Cr | ₹722 Cr |
Changes In working Capital | ₹-295 Cr | ₹-292 Cr | ₹-620 Cr |
Cash Flow after changes in Working Capital | ₹673 Cr | ₹936 Cr | ₹742 Cr |
Cash Flow from Operating Activities | ₹484 Cr | ₹766 Cr | ₹598 Cr |
Cash Flow from Investing Activities | ₹-1,339 Cr | ₹-1,812 Cr | ₹-4,480 Cr |
Cash Flow from Financing Activities | ₹818 Cr | ₹794 Cr | ₹3,977 Cr |
Net Cash Inflow / Outflow | ₹-37 Cr | ₹-251 Cr | ₹94 Cr |
Opening Cash & Cash Equivalents | ₹85 Cr | ₹262 Cr | ₹152 Cr |
Cash & Cash Equivalent on Amalgamation / Take over / Merger | - | ₹77 Cr | - |
Cash & Cash Equivalent of Subsidiaries under liquidations | - | - | ₹11 Cr |
Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - |
Effect of Foreign Exchange Fluctuations | ₹5.15 Cr | ₹-2.04 Cr | ₹4.22 Cr |
Closing Cash & Cash Equivalent | ₹53 Cr | ₹85 Cr | ₹262 Cr |
Compare Cashflow Statement of peers of PIRAMAL PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
PIRAMAL PHARMA | ₹19,711.2 Cr | -3% | 2.8% | 108.3% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹370,757.0 Cr | 1.6% | -3.7% | 60% | Stock Analytics | |
CIPLA | ₹109,559.0 Cr | -2% | -4.6% | 49.9% | Stock Analytics | |
DIVIS LABORATORIES | ₹103,416.0 Cr | -0.9% | 4.2% | 14.3% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹99,088.9 Cr | -2.1% | -0.9% | 89.1% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹97,939.0 Cr | -3.1% | -4.7% | 21.6% | Stock Analytics |
PIRAMAL PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
PIRAMAL PHARMA | -3% |
2.8% |
108.3% |
SENSEX | -0.6% |
-2.1% |
18.4% |
You may also like the below Video Courses